FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Articles|November 10, 2020
PREVIEW of AHA 2020 Scientific Sessions: Late-breaking Science, Days 4 and 5
Author(s)Grace Halsey
Preview days 4 and 5 of the American Heart Association 2020 live late-breaking science sessions. Decide what you need to watch and when.
Advertisement
The American Heart Association 2020 Scientific Sessions continue on Monday and Tuesday, November 16 and 17, and include
To help your advance planning, click through the agenda for each session, below. For Friday, Saturday, and Sunday's sessions, click here .
Advertisement
Related to this article
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
5